Neurocrine Biosciences, Inc.
Table of Contents

 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): February 7, 2006
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
         
Delaware   0-22705   33-0525145
(State or other
jurisdiction of
incorporation or
organization) 		  (Commission File
Number) 		  (IRS Employer Identification
No.)
     
12790 El Camino Real   92130
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: (858) 617-7600
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
o
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
    
o
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
    
o
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
 
    
o
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
 

 

TABLE OF CONTENTS

ITEM 1.01 ENTRY INTO MATERIAL DEFINITIVE AGREEMENT.
Item 9.01. Exhibits
SIGNATURES
EXHIBIT INDEX
EXHIBIT 10.1

Table of Contents

Table of Contents
ITEM 1.01 ENTRY INTO MATERIAL DEFINITIVE AGREEMENT.
     On February 7, 2006, Neurocrine Biosciences, Inc. entered into an amendment to their agreement dated July 20, 2001 with Glaxo Group Limited (GGL), a subsidiary of GlasoSmithKline (GSK). Under terms of this amendment, certain milestone events and payment terms were amended, as per the Exhibit 10.1 filed with this Current Report on Form 8-K.
Item 9.01. Exhibits
     
10.1
  Amended agreement with GlaxoSmithKline dated February 7, 2006

 

Table of Contents

Table of Contents
SIGNATURES
     Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
         
Dated: February 13, 2006  NEUROCRINE BIOSCIENCES, INC.
 		  
  /s/ PAUL W. HAWRAN    
  Paul W. Hawran   
  Executive Vice President and Chief Financial Officer   
 

 

Table of Contents

EXHIBIT INDEX
     
Exhibit    
Number   Document Description
10.1
  Amendment dated February 7, 2006, to the Collaboration and License Agreement between the Registrant and Glaxo Group Limited dated July 20, 2001.